ArticleNeurology2013
Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis.
Article in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.International journal of molecular sciences · 2025Pooled it
- Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.PloS one · 2017Pooled it
- Human antibody profiling technologies for autoimmune disease.Immunologic research · 2023Review
- Developments and Applications of Functional Protein Microarrays.Molecular & cellular proteomics : MCP · 2020Review
- The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis.International journal of molecular sciences · 2019Review
- Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2018Article
- High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction.Nature genetics · 2018Article
- Methodological Challenges in Protein Microarray and Immunohistochemistry for the Discovery of Novel Autoantibodies in Paediatric Acute Disseminated Encephalomyelitis.International journal of molecular sciences · 2017Article
- Multiple sclerosis: an example of pathogenic viral interaction?Virology journal · 2017Review
- Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.Molecular & cellular proteomics : MCP · 2016Article
- Anoctamin 2 identified as an autoimmune target in multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.Nature reviews. Neurology · 2015Review
- Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins.Frontiers in immunology · 2015Article
- Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus.PloS one · 2015Article
- EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy.PloS one · 2015Article
- B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.Science translational medicine · 2014Article
- B cells in MS and NMO: pathogenesis and therapy.Seminars in immunopathology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo profile the reactivity of CSF-derived immunoglobulin from patients with multiple sclerosis (MS) against a large panel of antigens, to identify disease-specific reactivities.
methodsCSF from subjects with MS with elevated immunoglobulin G and CSF from control subjects presenting with other inflammatory neurologic disease were screened against a protein array consisting of 9,393 proteins. Reactivity to a candidate protein identified using these arrays was confirmed with ELISA and immunocytochemistry.
resultsAutoantibodies against one protein on the array, recombination signal binding protein for immunoglobulin kappa J region (RBPJ), discriminated between patients with MS and controls (p = 0.0052). Using a large validation cohort, we found a higher prevalence of autoantibodies against RBPJ in the CSF of patients with MS (12.5%) compared with the CSF of patients with other neurologic diseases (1.6%; p = 0.02) by ELISA. This difference in reactivity was restricted to the CSF as serum reactivity against RBPJ did not differ between patients and controls. The presence of CSF autoantibodies against RBPJ was further confirmed by immunocytochemistry.
conclusionsThese data indicate that RBPJ, a ubiquitous protein of the Notch signaling pathway that plays an important role in Epstein-Barr virus infection, is a novel MS autoantigen candidate that is recognized by CSF-derived immunoglobulin G in a subset of patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.